{
  "id": "61f58a1a882a024a10000009",
  "type": "yesno",
  "question": "Is Daprodustat effective for anemia?",
  "ideal_answer": "Yes. Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33597868",
    "http://www.ncbi.nlm.nih.gov/pubmed/31306555",
    "http://www.ncbi.nlm.nih.gov/pubmed/34739194",
    "http://www.ncbi.nlm.nih.gov/pubmed/34713596",
    "http://www.ncbi.nlm.nih.gov/pubmed/27978511",
    "http://www.ncbi.nlm.nih.gov/pubmed/33628028",
    "http://www.ncbi.nlm.nih.gov/pubmed/32250021",
    "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
    "http://www.ncbi.nlm.nih.gov/pubmed/33744933",
    "http://www.ncbi.nlm.nih.gov/pubmed/31640478",
    "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
    "http://www.ncbi.nlm.nih.gov/pubmed/33561857"
  ],
  "snippets": [
    {
      "text": "CONCLUSIONS: Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33561857",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor (PHI) Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is non-inferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: haemoglobin efficacy and cardiovascular safety.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33744933",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33628028",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Once-daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in Japanese peritoneal dialysis participants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33964183",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34713596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ONCLUSIONS: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739196",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739194",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34739194",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of anemia of chronic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31640478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Daprodustat (GSK1278863) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease (CKD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27978511",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed for treating anemia of chronic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31306555",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Daprodustat is under development as an emerging new class of agents for the treatment of anemia associated with chronic kidney disease (CKD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32250021",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Daprodustat was efficacious and well tolerated for anemia in both NDD and DD patients in the short term based on current RCTs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33597868",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "And daprodustat may become an effective alternative for treatment of anemia with CKD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33597868",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}